미국 · 보도자료 · NGNE · 2026-10-05 20:01
뉴로진, 나스닥 규정 기반 신규 인재 유치용 주식보상 부여
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 8,340 shares of the Company’s common stoc
